Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

SMASH-HCM

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular...

Funding Programme
Start Date
End Date
Total Funding
€ 8 546 366
European Countries Involved

Structural and biophysical characterisation of insulin receptor and glutamate receptors AMPAR and NMDAR in complex with SorCS coreceptors 1 and 2

SorCS

Type II diabetes (T2D), Alzheimer’s Disease (AD) and Parkinson’s disease (PD) are common age-related diseases, which have reached endemic levels and become a burden for the global health. Lifestyle and environment are risk factors, but cannot explain all cases - genes also predispose for these diseases. Common for T2D, AD and PD is abnormal cell...

Funding Programme
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms

SYNAPSING

Disrupted neuronal connectivity and synapse dysfunction can manifest clinically as a range of emotional, behavioural and cognitive symptoms that are common to, and often overlapping in, mental disorders (MDs) such as major depressive disorder, bipolar disorder and schizophrenia and neurodegenerative disorders (NDs) such as Alzheimers disease and...

Funding Programme
Start Date
End Date
Total Funding
€ 6 999 921
European Countries Involved

Synaptic resilience in Tau-induced neurodegeneration

Hibernating_Synapses

Dementia is an enormous burden on society. Patients require life-long care and there is no cure or symptomatic treatment. At early phases, dementia is closely associated with synaptic degeneration and this correlates well with Tau pathology in >20 Tauopathies. Interestingly, historic observations in hamsters and squirrels show that when they enter...

Funding Programme
Start Date
End Date
Total Funding
€ 2 500 000
European Countries Involved

Tandem Repeats Associated with Neurogenomic Somatic Instability and Neurodegeneration

TRANSIT-ND

"Dementia and other neurodegenerative diseases are among the leading causes of disability worldwide and have an immense societal impact due to lack of effective treatments. For developing better preventive and therapeutic strategies, it is essential to clarify their still largely elusive genetic basis and pathophysiology. Emerging insights from the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 495 557
European Countries Involved

Targeting Circadian Clock Dysfunction in Alzheimer’s Disease

TClock4AD

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes...

Funding Programme
Start Date
End Date
Total Funding
€ 3 811 636

TArgeting Multiphosphorylated tau in Blood for non-invasive Alzheimer's Disease diagnosis and staging

TAMBO-AD

Alzheimer's disease (AD) is the major cause of dementia. The disease has an escalating impact on public health due to an increasing prevalence among the aging population in Europe and globally. In light of the first disease-modifying therapies becoming available, early diagnosis and precise disease staging are crucial for timely implementation of...

Funding Programme
Start Date
End Date
Total Funding
€ 217 076
European Countries Involved

Targeting the interrelation between microglia, neurons, and astrocytes to counteract tau-mediated synaptic impairments and neurodegeneration in AD.

SynapTau

The overall aim of SynapTau is to evaluate the contribution of microglia on tau-mediated synaptic loss in Alzheimers disease (AD), based on synaptosomal changes, which may help to develop therapeutic strategies against AD. Determining the impact of tau accumulation on synaptic loss is critical since it correlates with cognitive decline in AD...

Funding Programme
Start Date
End Date
Total Funding
€ 195 914
European Countries Involved

Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's Disease

NeutrAD

With the NeutrAD ERC PoC project, we present the first disease-modifying Alzheimers Disease (AD) drugs that abrogate leukocyte-mediated neurotoxicity and represent a novel class of drugs in the treatment of AD.AD is a neurological disorder characterized by progressive deterioration of cognitive function and leads to death within 3-9 years after...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Tau, a molecular modulator of neuronal energy managment

EnergizeTau

"The intraneuronal somatodendritic ""missorting"" and aggregation of Tau are pathological hallmarks in neurodegenerative diseases (NDDs) like and Alzheimer's disease (AD), and are thought to be drivers of neurotoxicity. That NDDs manifesting with Tau ""missorting"" present with (neuro)metabolic abnormalities, often prior to pathology onset, is...

Funding Programme
Start Date
End Date
Total Funding
€ 2 194 940
European Countries Involved

Terahertz Ultra Strong Coupling for mAcromolecules structure aNalYse & control

TUSCany

MacroMolecules (e.g Proteins, DNA) carry out most of the functions of the living and these functions come from their 3D-structure. For instance, foldopathy like Alzheimers and Parkinsons disease are caused by misfolding of proteins. Modifying this structure non-invasively is consequently a tremendous challenge for both microbiology research and...

Funding Programme
Start Date
End Date
Total Funding
€ 1 999 555
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).